Ropes & Gray represented KalVista Pharmaceuticals in a licensing agreement with Kaken Pharmaceuticals to commercialize KalVista’s investigational oral on-demand therapy, sebetralstat, in Japan for treatment targeting a rare genetic disease called hereditary angioedema. The transaction was announced on April 8.
The Ropes & Gray team included life sciences licensing partner Hannah England and life sciences licensing associate Mallory Ursul.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.